title: Chemokine to the rescue: interleukin-8 mediates resistance to PI3K-pathway-targeted therapy in breast cancer.
abstract: Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.
authors.affiliation: Oncology Research, Pfizer Worldwide Research and Development, 10777 Science Center Drive, CB3/1376, San Diego, CA 92121, USA. robert.abraham@pfizer.com
authors.forename: Robert T
authors.initials: RT
authors.lastname: Abraham